Indian Science Technology and Engineering facilities Map
 
Supplier Map
Service Map
Preivious Next  

  Digital Catalogue for Technology and Products Development


   Technology and Product Development

    Basic Information

Technology developed: Surface Modified Targeted Nanoparticles Carrying Shigella Antigens (TP19765228932)
Category: Product(Hardware/Material/Software)
Details of Inventor(s):
Inventor Institution/Organization/Company Department Designation
Dhirendra S. Katti IIT Kanpur BSBE Professor
Namrata Baruah IIT Kanpur
Technical Application Area: Healthcare
If 'Other', please specify:
Please give more details of new technical application area:
Organization(s):
Indian Institute of Technology (IIT) Kanpur
Affiliated Ministry: Ministry of Education
Type of technology development: Indigenous
Does the technology help in replacing any import items currently
procured from outside India?
Yes
Does the technology have export potential? Yes
Category of Technology developed: Immediate Deployment
Stage of Development: Lab-scale
Please describe in detail including the TRL Level:
The plan is being executed

    Abstract:

Applications: Shigellosis is a diarrheal disease caused by a group of bacteria called Shigella, responsible for the death of greater than 0.2 million people in 2016. The situation is aggravated by Shigella strains acquiring antibiotic resistance. Unfortunately, no commercial vaccines are available till date. An effective Shigella vaccine would be one that provides cross-protection against multiple species of Shigella. Herein, we developed 3 intranasal nanovaccines against Shigella made of PLGA encapsulating conserved proteins and or LPS of S. dysenteriae 1 origin that provided around 80 per cent protection against S. flexneri 2a, one of the most common serotypes in circulation. Since, the current innovation involves simple, non-invasive, intranasal nanovaccines with greater shelf life, we expect these to be amenable for mass production and immunization
Advantages: Intranasal Shigella nanovaccines having application in Single or multi-antigen system showing cross-protection against Shigella. Nasal drop formulation. Hence, ease of dosing and scale-up. The lyophilization of the nanovaccines helps increase the shelf-life. More patient compliance leading to ease of mass immunization

    Technology Inputs:

Imported Equipment/Spare Parts:
Equipment/Spare Parts Year ITC-HS Code
NA
Indigenous Equipment/Spare Parts:
Equipment/Spare Parts Year ITC-HS Code
NA
Imported Raw Materials:
Raw Materials Year ITC-HS Code
NA
Indigenous Raw Materials:
Raw Materials Year ITC-HS Code
NA
Existing R&D Facilities used:
Facilities Year ITC-HS Code
NA

   Patents & Publications:

Patents:
Filed Patents (No.) Granted Patents (No.) Year
1 0 2020-21
Publications:
Submitted (No.) Published (No.) Year
0 1 2020-21

    Commercialization Potential:

Who are the Potential Licensees? GlaxoSmithKline, Sanofi Aventis, Pfizer
What commercially available products address
the same problem?
Company Product Problem Addressed
Would you like to develop this invention further with
corporate research support?
Yes
Would you be interested in participating in cluster based
programs for commercialization research or business
planning for your invention?
Yes
      Submitted by: J.G. Rao Date of Submission: 5-5-2022



Chat Room      Write Review     Talk to Experts


THE VISION
THE MISSION
ABOUT I-STEM
It has always been the basic tenet of the Government of India, in generously funding R&D efforts at academic institutions over the years, that facilities established through such support be made available to those needing them and qualified to make use of them for their own research work
read more >>

However, this was never easy or straightforward for, among other reasons, there was no ready source of information of what facility was available and where. Thanks to the Web, it is much easier today to have a national and regional “inventory of resources”, so as to match users with the resources they need, and to do all this in an efficient and transparent manner.

This can lead to a leap in R&D productivity and greatly enhance the effectiveness of public investment. This is the motivation behind I-STEM.
read less <<
Visitor Hit Counter
Hosted at Indian Institute of Science
Copyright © 2024 I-STEM. All rights reserved.
Audited by: STQC Bengaluru.